Cost-effectiveness of budesonide/formoterol for maintenance and reliever asthma therapy in Denmark--cost-effectiveness analysis based on five randomised controlled trials

Jannie Wickstrøm; Nanna Dam; Irena Malmberg; Brian Bekker Hansen; Peter Lange

doi:http://dx.doi.org/10.1111/j.1752-699X.2009.00134.x

Cost-effectiveness of budesonide/formoterol for maintenance and reliever asthma therapy in Denmark--cost-effectiveness analysis based on five randomised controlled trials

Jannie Wickstrøm, Nanna Dam, Irena Malmberg, Brian Bekker Hansen, Peter Lange

7 Citations (Scopus)

Abstract

Budesonide/formoterol maintenance and reliever therapy (Symbicort SMART) is an effective asthma-management regime where patients use budesonide/formoterol both as maintenance treatment and as additional doses as needed to improve overall asthma control by reducing symptoms and exacerbations. The aim of this study was to determine the cost-effectiveness of the Symbicort SMART regime in Denmark vs higher dose inhaled corticosteroid (ICS) plus reliever medication, similar dose inhaled corticosteroid/long-acting beta(2)-agonist (ICS/LABA) combination therapy plus reliever medication or higher dose of inhaled ICS/LABA combination therapy plus reliever medication.

Original language	English
Journal	Clinical Respiratory Journal
Volume	3
Issue number	3
Pages (from-to)	169-80
Number of pages	11
ISSN	1752-6981
DOIs	https://doi.org/10.1111/j.1752-699X.2009.00134.x
Publication status	Published - 2009

Access to Document

http://dx.doi.org/10.1111/j.1752-699X.2009.00134.x

Cite this

Cost-effectiveness of budesonide/formoterol for maintenance and reliever asthma therapy in Denmark--cost-effectiveness analysis based on five randomised controlled trials. / Wickstrøm, Jannie; Dam, Nanna; Malmberg, Irena et al.

In: Clinical Respiratory Journal, Vol. 3, No. 3, 2009, p. 169-80.

Research output: Contribution to journal › Journal article › Research › peer-review

@article{11b493115f454aa0915e48ec5e039519,

title = "Cost-effectiveness of budesonide/formoterol for maintenance and reliever asthma therapy in Denmark--cost-effectiveness analysis based on five randomised controlled trials",

abstract = "Budesonide/formoterol maintenance and reliever therapy (Symbicort SMART) is an effective asthma-management regime where patients use budesonide/formoterol both as maintenance treatment and as additional doses as needed to improve overall asthma control by reducing symptoms and exacerbations. The aim of this study was to determine the cost-effectiveness of the Symbicort SMART regime in Denmark vs higher dose inhaled corticosteroid (ICS) plus reliever medication, similar dose inhaled corticosteroid/long-acting beta(2)-agonist (ICS/LABA) combination therapy plus reliever medication or higher dose of inhaled ICS/LABA combination therapy plus reliever medication.",

author = "Jannie Wickstr{\o}m and Nanna Dam and Irena Malmberg and Hansen, {Brian Bekker} and Peter Lange",

year = "2009",

doi = "http://dx.doi.org/10.1111/j.1752-699X.2009.00134.x",

language = "English",

volume = "3",

pages = "169--80",

journal = "Clinical Respiratory Journal",

issn = "1752-6981",

publisher = "Wiley-Blackwell",

number = "3",

}

TY - JOUR

T1 - Cost-effectiveness of budesonide/formoterol for maintenance and reliever asthma therapy in Denmark--cost-effectiveness analysis based on five randomised controlled trials

AU - Wickstrøm, Jannie

AU - Dam, Nanna

AU - Malmberg, Irena

AU - Hansen, Brian Bekker

AU - Lange, Peter

PY - 2009

Y1 - 2009

N2 - Budesonide/formoterol maintenance and reliever therapy (Symbicort SMART) is an effective asthma-management regime where patients use budesonide/formoterol both as maintenance treatment and as additional doses as needed to improve overall asthma control by reducing symptoms and exacerbations. The aim of this study was to determine the cost-effectiveness of the Symbicort SMART regime in Denmark vs higher dose inhaled corticosteroid (ICS) plus reliever medication, similar dose inhaled corticosteroid/long-acting beta(2)-agonist (ICS/LABA) combination therapy plus reliever medication or higher dose of inhaled ICS/LABA combination therapy plus reliever medication.

AB - Budesonide/formoterol maintenance and reliever therapy (Symbicort SMART) is an effective asthma-management regime where patients use budesonide/formoterol both as maintenance treatment and as additional doses as needed to improve overall asthma control by reducing symptoms and exacerbations. The aim of this study was to determine the cost-effectiveness of the Symbicort SMART regime in Denmark vs higher dose inhaled corticosteroid (ICS) plus reliever medication, similar dose inhaled corticosteroid/long-acting beta(2)-agonist (ICS/LABA) combination therapy plus reliever medication or higher dose of inhaled ICS/LABA combination therapy plus reliever medication.

U2 - http://dx.doi.org/10.1111/j.1752-699X.2009.00134.x

DO - http://dx.doi.org/10.1111/j.1752-699X.2009.00134.x

M3 - Journal article

SN - 1752-6981

VL - 3

SP - 169

EP - 180

JO - Clinical Respiratory Journal

JF - Clinical Respiratory Journal

IS - 3

ER -

Cost-effectiveness of budesonide/formoterol for maintenance and reliever asthma therapy in Denmark--cost-effectiveness analysis based on five randomised controlled trials

Abstract

Access to Document

Fingerprint

Cite this